SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Financials Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.
Equities
688180
CNE1000041Z1
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.19 CNY | +2.53% |
|
+0.72% | -30.22% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,711 | 64,649 | 56,686 | 57,119 | 35,947 | 24,762 | - | - |
| Enterprise Value (EV) 1 | 18,402 | 62,115 | 53,714 | 52,363 | 33,904 | 21,723 | 22,386 | 22,807 |
| P/E ratio | -24.9 x | -23.4 x | -59.1 x | - | -7.62 x | -7.05 x | -9.5 x | -11.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.1 x | 40.5 x | 14.1 x | 39.3 x | 23.9 x | 11.6 x | 7.95 x | 8.36 x |
| EV / Revenue | 23.7 x | 38.9 x | 13.3 x | 36 x | 22.6 x | 10.2 x | 7.19 x | 7.7 x |
| EV / EBITDA | -23.5 x | -41.7 x | -127 x | -21.7 x | -16 x | -16 x | -20.3 x | -25.9 x |
| EV / FCF | -9.3 x | -30.5 x | -38 x | -24.1 x | -12.8 x | -10.7 x | -13.5 x | -16.3 x |
| FCF Yield | -10.8% | -3.28% | -2.63% | -4.14% | -7.8% | -9.3% | -7.42% | -6.12% |
| Price to Book | 6.26 x | 7.14 x | 5.17 x | - | 2.43 x | 1.55 x | 1.7 x | 1.62 x |
| Nbr of stocks (in thousands) | 784,147 | 872,496 | 910,757 | 982,872 | 985,011 | 984,874 | - | - |
| Reference price 2 | 23.86 | 47.81 | 47.26 | 42.83 | 17.67 | 11.17 | 11.17 | 11.17 |
| Announcement Date | 02/03/20 | 26/02/21 | 25/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 775.1 | 1,595 | 4,025 | 1,453 | 1,503 | 2,129 | 3,113 | 2,963 |
| EBITDA 1 | -783.5 | -1,490 | -422 | -2,417 | -2,122 | -1,360 | -1,101 | -880 |
| EBIT 1 | -747.3 | -1,636 | -558.3 | -2,666 | -2,377 | -1,552 | -750.3 | -1,129 |
| Operating Margin | -96.41% | -102.59% | -13.87% | -183.41% | -158.19% | -72.87% | -24.1% | -38.11% |
| Earnings before Tax (EBT) 1 | -763.1 | -1,672 | -595 | -2,677 | -2,490 | -1,551 | -746.3 | -43.62 |
| Net income 1 | -747.4 | -1,669 | -720.9 | -2,388 | -2,282 | -1,462 | -729.5 | -85.17 |
| Net margin | -96.43% | -104.62% | -17.91% | -164.3% | -151.85% | -68.65% | -23.43% | -2.87% |
| EPS 2 | -0.9600 | -2.040 | -0.8000 | - | -2.320 | -1.583 | -1.175 | -0.9566 |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,643 | -2,021 | -1,661 | -1,395 |
| FCF margin | -255.28% | -127.71% | -35.14% | -149.31% | -175.92% | -94.92% | -53.35% | -47.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 02/03/20 | 26/02/21 | 25/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 309 | 2,534 | 2,972 | 4,756 | 2,043 | 3,039 | 2,377 | 1,956 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,643 | -2,014 | -1,661 | -1,395 |
| ROE (net income / shareholders' equity) | -23.6% | -37.7% | -10.4% | -32.7% | -27.4% | -23.1% | -11.5% | -0.15% |
| ROA (Net income/ Total Assets) | -17.1% | -26.8% | -9.24% | - | -19.1% | -14.7% | -6.78% | -0.61% |
| Assets 1 | 4,360 | 6,228 | 7,802 | - | 11,969 | 9,964 | 10,767 | 13,863 |
| Book Value Per Share 2 | 3.810 | 6.690 | 9.150 | - | 7.270 | 7.200 | 6.550 | 6.890 |
| Cash Flow per Share 2 | -0.9100 | -1.780 | -0.7200 | - | -2.050 | -1.220 | -0.5700 | - |
| Capex 1 | 792 | 580 | 772 | 394 | 628 | 610 | 610 | 400 |
| Capex / Sales | 102.13% | 36.4% | 19.19% | 27.1% | 41.81% | 28.63% | 19.58% | 13.5% |
| Announcement Date | 02/03/20 | 26/02/21 | 25/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.17
CNY
Average target price
16.09
CNY
Spread / Average Target
+44.12%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.97% | 94.74B | |
| -4.08% | 37.28B | |
| -11.87% | 32.68B | |
| +74.97% | 27.72B | |
| -13.38% | 16.19B | |
| -2.42% | 13.88B | |
| -11.67% | 11.58B | |
| +190.36% | 10.92B | |
| -52.61% | 9.54B |
- Stock Market
- Equities
- 1877 Stock
- 688180 Stock
- Financials Shanghai Junshi Biosciences Co., Ltd.
